Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 3/2020

28.11.2019 | Original Article

Shiga toxin-producing Escherichia coli in household members of children with hemolytic uremic syndrome

verfasst von: Laura Fernanda Alconcher, Marta Rivas, Lucas Ivan Lucarelli, Jimena Galavotti, Mabel Rizzo

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

The objective is to establish the frequency of STEC infections in household contacts of HUS patients. We studied 292 household contacts of 82 HUS patients attended from 2010 to 2018. In HUS cases, diagnostic criteria were (1) isolation and characterization of STEC strains, (2) detection of free fecal Shiga toxin (FFStx), and (3) detection of anti-O serogroup-specific antibodies. Contacts were studied by screening of stx genes by polymerase chain reaction and/or STEC isolation from stool samples. Clonal relation of STEC strains was established by pulsed-field gel electrophoresis (PFGE). Frequencies of HUS patients without STEC isolation with STEC-positive contacts were determined. Serotypes and stx-genotypes in patients and contacts were analyzed. Thirty (36.6%) HUS patients had 36 STEC-positive contacts. Fourteen (38.8%) were children, 20 adults, and 2 dogs. One sibling developed HUS, 6 contacts had gastrointestinal symptoms, and the rest were asymptomatic. In 5 of 30 HUS patients, STEC infection could not be confirmed, and 2 cases were diagnosed only by FFStx detection. Of the remaining 23 HUS patients, 16 had E. coli O157 and 7 E. coli O145 infection. Serotype and/or stx-genotype concordance was established in 19 (83%) of 23 HUS patients and their contacts. Five HUS cases and their contacts studied by PFGE showed macrorestriction patterns with more than 90% similarity. Nearly one third of HUS patients had STEC-positive family contacts, and one third of them were children. Early identification is important to prevent ongoing contamination among family and institutional contacts and to facilitate prompt detection of HUS in STEC-positive contacts.
Literatur
1.
Zurück zum Zitat Gianantonio C, Vitacco M, Mendilaharzu F, Rutty A, Mendilaharzu J (1964) The hemolytic uremic syndrome. J Pediatr 64:478–491CrossRef Gianantonio C, Vitacco M, Mendilaharzu F, Rutty A, Mendilaharzu J (1964) The hemolytic uremic syndrome. J Pediatr 64:478–491CrossRef
2.
Zurück zum Zitat Gyles CL (2007) Shiga toxin-producing Escherichia coli: an overview. J. Anim. Sci. 85:E45–E62CrossRef Gyles CL (2007) Shiga toxin-producing Escherichia coli: an overview. J. Anim. Sci. 85:E45–E62CrossRef
3.
Zurück zum Zitat Karmali MA, Steele BT, Petric M, Lim C (1983) Sporadic cases of hemolytic uremic syndrome associated with fecal cytotoxin and cytotoxin producing Escherichia coli. Lancet i:619–620CrossRef Karmali MA, Steele BT, Petric M, Lim C (1983) Sporadic cases of hemolytic uremic syndrome associated with fecal cytotoxin and cytotoxin producing Escherichia coli. Lancet i:619–620CrossRef
4.
Zurück zum Zitat Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H (1985) The association between hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 151:775–782CrossRef Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H (1985) The association between hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 151:775–782CrossRef
6.
Zurück zum Zitat Karmali MA (2004) Infection by Shiga toxin-producing Escherichia coli: an overview. Mol. Biotechnol. 26:117–122CrossRef Karmali MA (2004) Infection by Shiga toxin-producing Escherichia coli: an overview. Mol. Biotechnol. 26:117–122CrossRef
7.
Zurück zum Zitat Scheutz F, Teel LD, Beutin L, Pierard D, Buvens G, Karch H, Mellmann A, Caprioli A, Tozzoli R, Morabito S, Strockbine NA, Melton-Celsa AR, Sánchez M, Persson S, O‘Brien AD. (2012) A multi-center evaluation of a sequence-based protocol to subtype Shiga toxins and standardize Stx nomenclature. J. Clin. Microbiol. 50:2951–2963CrossRef Scheutz F, Teel LD, Beutin L, Pierard D, Buvens G, Karch H, Mellmann A, Caprioli A, Tozzoli R, Morabito S, Strockbine NA, Melton-Celsa AR, Sánchez M, Persson S, O‘Brien AD. (2012) A multi-center evaluation of a sequence-based protocol to subtype Shiga toxins and standardize Stx nomenclature. J. Clin. Microbiol. 50:2951–2963CrossRef
9.
Zurück zum Zitat Ludwig K, Sarkim V, Bitzan M, Karmali MA, Bobrowski C, Ruder H, Laufs R, Sobottka I, Petric M, Karch H, Müller-Wiefel D (2002) Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic uremic syndrome. J Clin Microbiol 40(5):1773–1782 Ludwig K, Sarkim V, Bitzan M, Karmali MA, Bobrowski C, Ruder H, Laufs R, Sobottka I, Petric M, Karch H, Müller-Wiefel D (2002) Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic uremic syndrome. J Clin Microbiol 40(5):1773–1782
10.
Zurück zum Zitat Rivas M, Miliwebsky E, Chinen I, Roldán CD, Balbi L, García B, Fiorilli G, Sosa-Estani S, Kincaid J, Rangel J, Griffin PM, the Case-Control Study Group (2006) Characterization and epidemiologic subtyping of Shiga toxin-producing Escherichia coli strains isolated from hemolytic uremic syndrome and diarrhea cases in Argentina. FoodbornePathog. Dis. 3:88–96CrossRef Rivas M, Miliwebsky E, Chinen I, Roldán CD, Balbi L, García B, Fiorilli G, Sosa-Estani S, Kincaid J, Rangel J, Griffin PM, the Case-Control Study Group (2006) Characterization and epidemiologic subtyping of Shiga toxin-producing Escherichia coli strains isolated from hemolytic uremic syndrome and diarrhea cases in Argentina. FoodbornePathog. Dis. 3:88–96CrossRef
11.
Zurück zum Zitat Zotta CM, Chinen I, Lavayén S, Cepeda M, Deza N, Morvay L, Carbonari C, Rearte A, Rivas M (2015) Escherichia coli in household contacts of cases of hemolytic uremic syndrome. Salud y Ciencia 21(2):136–141 Zotta CM, Chinen I, Lavayén S, Cepeda M, Deza N, Morvay L, Carbonari C, Rearte A, Rivas M (2015) Escherichia coli in household contacts of cases of hemolytic uremic syndrome. Salud y Ciencia 21(2):136–141
12.
Zurück zum Zitat Heuvelink AE, Van de Kar NC, Van Der Velden TJ, Chart H, Monnens LA (1999) Verocytotoxin producing Escherichia coli infection in household members of children with hemolytic-uremic syndrome in the Netherlands. Pediatr Infect Dis J 18(8):709–714CrossRef Heuvelink AE, Van de Kar NC, Van Der Velden TJ, Chart H, Monnens LA (1999) Verocytotoxin producing Escherichia coli infection in household members of children with hemolytic-uremic syndrome in the Netherlands. Pediatr Infect Dis J 18(8):709–714CrossRef
13.
Zurück zum Zitat Tokuda K, Yahata Y, Sunagawa T (2016) Prevention of secondary household transmission during Shiga toxin-producing Escherichia coli outbreaks. Epidemiol. Infect. 144:2931–2939CrossRef Tokuda K, Yahata Y, Sunagawa T (2016) Prevention of secondary household transmission during Shiga toxin-producing Escherichia coli outbreaks. Epidemiol. Infect. 144:2931–2939CrossRef
14.
Zurück zum Zitat Werber D, Mason BW, Evans MR, Salmon RL (2008) Preventing household transmission of Shiga toxin–producing Escherichia coli O157 infection: promptly separating siblings might be the key. Clin Infect Dis 46:1189CrossRef Werber D, Mason BW, Evans MR, Salmon RL (2008) Preventing household transmission of Shiga toxin–producing Escherichia coli O157 infection: promptly separating siblings might be the key. Clin Infect Dis 46:1189CrossRef
15.
Zurück zum Zitat Parry SM, Salmon RL (1998) Sporadic STEC O157 infections: secondary household transmission in Wales Emerg. Infect. Dis. 4:657–661CrossRef Parry SM, Salmon RL (1998) Sporadic STEC O157 infections: secondary household transmission in Wales Emerg. Infect. Dis. 4:657–661CrossRef
16.
Zurück zum Zitat Lopez EL, Diaz M, Devoto S, Grinstein S, Woloj M, Murray BE, Rubeglio E, Mendilaharzu F, Turco M, Vasquez M et al (1991) Evidence of infection with organisms producing Shiga-like toxins in household contacts of children with the hemolytic uremic syndrome. Pediatr Infect Dis J 10(1):20–24CrossRef Lopez EL, Diaz M, Devoto S, Grinstein S, Woloj M, Murray BE, Rubeglio E, Mendilaharzu F, Turco M, Vasquez M et al (1991) Evidence of infection with organisms producing Shiga-like toxins in household contacts of children with the hemolytic uremic syndrome. Pediatr Infect Dis J 10(1):20–24CrossRef
17.
Zurück zum Zitat Rivas M, Sosa-Estani S, Rangel J et al (2008) Risk factors for sporadic Shiga toxin-producing Escherichia coli infections in children, Argentina. Emerging Infectious Diseases 14:763–771CrossRef Rivas M, Sosa-Estani S, Rangel J et al (2008) Risk factors for sporadic Shiga toxin-producing Escherichia coli infections in children, Argentina. Emerging Infectious Diseases 14:763–771CrossRef
18.
Zurück zum Zitat Miliwebsky E, Deza N, Chinen I et al (2007) Prolonged fecal shedding of Shiga toxin-producing Escherichia coli among children attending day-care centers in Argentina. Rev Argent Microbiol 39:90–92PubMed Miliwebsky E, Deza N, Chinen I et al (2007) Prolonged fecal shedding of Shiga toxin-producing Escherichia coli among children attending day-care centers in Argentina. Rev Argent Microbiol 39:90–92PubMed
19.
Zurück zum Zitat Fernández Brando RJ, Bentancor LV, Mejías MP et al (2011) Antibody response to Shiga toxins in Argentinean children with enteropathic hemolytic uremic syndrome at acute and long-term follow-up periods. Plos One 6:e19–e136 Fernández Brando RJ, Bentancor LV, Mejías MP et al (2011) Antibody response to Shiga toxins in Argentinean children with enteropathic hemolytic uremic syndrome at acute and long-term follow-up periods. Plos One 6:e19–e136
20.
Zurück zum Zitat Jensen C, Schiellerup P, Olsen KEP, Scheutz F, Petersen E, Gerner-Smidt P, Mølbak K (2005) Antimicrobial treatment of asymptomatic carriers of verocytotoxin-producing Escherichia coli: an empiric study. Scand J Infect Dis 37(1):61–66CrossRef Jensen C, Schiellerup P, Olsen KEP, Scheutz F, Petersen E, Gerner-Smidt P, Mølbak K (2005) Antimicrobial treatment of asymptomatic carriers of verocytotoxin-producing Escherichia coli: an empiric study. Scand J Infect Dis 37(1):61–66CrossRef
Metadaten
Titel
Shiga toxin-producing Escherichia coli in household members of children with hemolytic uremic syndrome
verfasst von
Laura Fernanda Alconcher
Marta Rivas
Lucas Ivan Lucarelli
Jimena Galavotti
Mabel Rizzo
Publikationsdatum
28.11.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 3/2020
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-019-03738-1

Weitere Artikel der Ausgabe 3/2020

European Journal of Clinical Microbiology & Infectious Diseases 3/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.